68ga-nota-nectin-4 antibody fragment
Urothelial Carcinoma
Explore 163 assets in Urothelial Carcinoma →Floatz Rating
D30/100
Confidence
Indicative
Sponsor
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Modality
radiopharmaceutical
Development Phase
N/A
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
15Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06994078CT.gov Clinical Application of PET Imaging Targeting Nectin-4 in Malignant Tumors | — | Not Yet Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Urothelial Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| 68ga-nota-nectin-4 antibody fragment (this asset) | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | N/A | D · 30 |
| Cyclophosphamide | Beijing Biotech | P3 | BB |
| Pembrolizumab | Sutro Biopharma, Inc. | P3 | BB |
| Cis-Diamminedichloroplatinum Ii | Nagoya University | P3 | BB |
| Durvalumab | Alliance for Clinical Trials in Oncology | P3 | BB |
| Enfortumab Vedotin (Fully Human Monoclonal Antibody Conjugated To A Cytotoxic Agent Monomethyl Auristatin E (Mmae) Targeting Nectin-4) | Vasgene Therapeutics, Inc | P2/3 | BB |
| Immunoglobulin G1, Anti-(Human Vascular Endothelial Growth Factor Receptor Type Vegfr-2 Extracellular Domain) (Human Monoclonal Imc-1121B .Gamma.-Chain), Disulphide With Human Monoclonal Imc-1121B .Kappa.-Chain, Dimer | Eli Lilly and Company | P3 | BB |
| Docetaxel | NuCana plc | P3 | BB |
| Retifanlimab | Incyte Corporation | P2 | BB |
+42 more in the Urothelial Carcinoma cohort
Other indications for 68ga-nota-nectin-4 antibody fragment
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Lung Carcinoma | — | N/A | D · 30 |
| Breast Cancer | — | N/A | D · 26 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
- CyclophosphamideBeijing BiotechBB
- PembrolizumabSutro Biopharma, Inc.BB
- Cis-Diamminedichloroplatinum IiNagoya UniversityBB
- DurvalumabAlliance for Clinical Trials in OncologyBB
- Enfortumab Vedotin (Fully Human Monoclonal Antibody Conjugated To A Cytotoxic Agent Monomethyl Auristatin E (Mmae) Targeting Nectin-4)Vasgene Therapeutics, IncBB
Citation
Floatz Terminal. 68ga-nota-nectin-4 antibody fragment in Urothelial Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/68ga-nota-nectin-4-antibody-fragment-urothelial-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →